On May 5, 2014 Cyclacel Pharmaceuticals reported that the Japanese Patent and Trademark Office issued two patents broadening the exclusivity of sapacitabine, the company’s lead clinical candidate (Press release Cyclacel, MAY 5, 2014, View Source [SID:1234500485]). Japanese Patent 5443763 claims novel pharmaceutical formulations of sapacitabine. Japanese Patent 5457196 claims methods of treating cancer comprising sapacitabine in combination with histone deacetylase (HDAC) inhibitors. Equivalent patents have been granted in the United States and other countries.